Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-agent JNJ-56022473 in MDS and AML patients failing hypomethylating therapy
2016-000327-10Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talacotuzumab in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by GWT-TUD. Primary endpoint: Overall hematological response rate at 3 months. Started Jul 2016; status: completed.
02
Drugs
talacotuzumab
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-000327-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000327-10.